In times of crisis, adapting our programs to continue to serve you becomes our priority.

Make a donation

Friday, May 22 2020

Myeloma Matters: May 2020

  • COVID-19 section on
  • COVID-19 related webinars
  • Daratumumab, Lenalidomide, Bortezomib, & Dexamethasone for Transplant-eligible Newly Diagnosed Multiple Myeloma Study
  • Janssen Presents First Data from Phase 1 Study of BCMAxCD3 Bispecific Teclistamab in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma
  • Multipe Myeloma Patient Advocacy Engagement Survey (COVID-19 Assessment)
  • Myeloma Canada Survey for Patients:
  • The Method of Administering Daratumumab
  • The Myeloma Priority Setting Partnership Survey #2: Coming Soon to an Inbox Near You!
  • The Multiple Myeloma March Welcomes Bristol Myers Squibb and their Move for Myeloma Challenge
  • Let's get started! Sign up to one of the participating cities across the country:
  • New InfoVideo is now online!
  • Spotlight on Ellis Basevitz
  • Upcoming events
  • In the community